Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Molly K. Moloney"'
Autor:
Mehdi Michel Djamel Numa, Molly K. Moloney, Nambu Mitchell David, Robert R. Webb, Michael Trzoss, Mili Kapoor, Jonathan A. Covel, Quinlyn A. Soltow, Mitchell Mutz, Xiaoming Li, Peter J. Webb
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:2465-2471
A novel antifungal strategy targeting the inhibition of calcineurin is described. To develop a calcineurin based inhibitor of pathogenic fungi, analogs of FK506 were synthesized that were able to permeate mammalian but not fungal cells. Antagonists i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e21264582bc6932ed420f6836aaa6ac4
https://doi.org/10.1016/j.bmcl.2017.04.004
https://doi.org/10.1016/j.bmcl.2017.04.004
Publikováno v:
Antimicrobial Agents and Chemotherapy. 64
Manogepix (MGX) targets the conserved fungal Gwt1 enzyme required for acylation of inositol early in the glycosylphosphatidylinositol biosynthesis pathway. The prodrug fosmanogepix is currently in clinical development for the treatment of invasive fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36e402987a3ee4a2a60ca22ba20d0856
https://doi.org/10.1128/aac.01387-19
https://doi.org/10.1128/aac.01387-19
Autor:
Quinlyn A. Soltow, Jonathan A. Covel, Peter J. Webb, Karen Joy Shaw, Marc D. Sharp, Michael Trzoss, Mili Kapoor, Molly K. Moloney
Publikováno v:
Medicinal Chemistry Reviews ISBN: 9780996293280
Medicinal Chemistry Reviews
Medicinal Chemistry Reviews
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71579f0a5afd254384e8c0605e33853b
https://doi.org/10.29200/acsmedchemrev-v54.ch10
https://doi.org/10.29200/acsmedchemrev-v54.ch10
Autor:
Jennifer L. Tenor, Jonathan Covel, Mili Kapoor, Michael Trzoss, Charles Giamberardino, John R. Perfect, Wiley A. Schell, Molly K. Moloney, Peter Webb, Quinlyn A. Soltow, Karen Joy Shaw, Gisele Duboc, Dena L. Toffaletti
Publikováno v:
Antimicrobial Agents and Chemotherapy
Cryptococcal meningitis (CM), caused primarily by Cryptococcus neoformans, is uniformly fatal if not treated. Treatment options are limited, especially in resource-poor geographical regions, and mortality rates remain high despite current therapies.<
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecef677b685f4cce3e01a68e50ec3809
https://doi.org/10.1128/aac.00523-18
https://doi.org/10.1128/aac.00523-18
Autor:
Mili Kapoor, Quinlyn A. Soltow, Michael Trzoss, Molly K. Moloney, Jonathan A. Covel, Peter J. Webb, Karen Joy Shaw
Publikováno v:
Bioorg Med Chem Lett
Fosmanogepix (APX001) is a first-in-class prodrug molecule that is currently in Phase 2 clinical trials for invasive fungal infections. The active moiety manogepix (APX001A) inhibits the novel fungal protein Gwt1. Gwt1 catalyzes an early step in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b8755e5c3c69d6cf0c5a88586a4b7a1
https://doi.org/10.1016/j.bmcl.2019.126713
https://doi.org/10.1016/j.bmcl.2019.126713